Recent Finacing
Recent Raise
Ouro Medicines develops therapies for B cell–driven diseases, advancing a BCMA-directed bispecific T‑cell engager licensed from Keymed with rights outside Greater China and protein-engineering pipeline targeting B cell subsets.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
